Establishment of a high-throughput screening system for universal anti-HIV targets

Chinese Science Bulletin

Volumn 55, Issue 10, 2010, Pages 937-942

  Yin, Qi ^a,b   Zhuang, Dao Ming ^c   Jiang, Ya Qin ^a,b   Zhao, Chuan Ke ^a,b   Zeng, Xin ^a,b   Li, Shi You ^a  

^a Chinese Academy of Sciences   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

High throughput screening; HIV 1; Inhibitor; Virus cell based assay

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77952040968     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-009-0739-5     Document Type: Article

References (35)

1. Hartzell J D, Janke I E, Weintrob A C. Impact of depression on HIV outcomes in the HAART era. J Antimicrob Chemother, 2008, 62: 246-255.
2. Nasoodi A, Lim L T, Al-Ani A, et al. What you can see in your patient's eyes? Review of ocular manifestations of HIV in HAART era. Intl J STD AIDS, 2008, 19: 4-11.
3. Aquaro S, Svicher V, Ronga L, et al. HIV-1-associated dementia during HAART therapy. Recent patents on CNS drug discovery, 2008, 3: 23-33.
4. Martins S, Ramos M J, Fernandes P A. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr Med Chem, 2008, 15: 1083-1095.
5. Schurmann D, Wesselmann H, Kurowski M, et al. Kaletra single agent HAART after intolerance of NRTI- and NNRTI-containing regimens following kidney transplantation. Infection, 2007, 35: 194-196.
6. Bongiovanni M, Gianotti N, Chiesa E, et al. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. Infection, 2007, 35: 451-456.
7. Apuzzo L G, Vaida F, Gallant J E, et al. Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr, 2009, 50: 267-275.
8. Young J, Rickenbach M, Weber R, et al. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antivir Ther, 2005, 10: 73-81.
9. Shafer R W, Schapiro J M. HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev, 2008, 10: 67-84.
10. Yeni P. Update on HAART in HIV. J Hepatol, 2006, 44: S100-S103.
11. Kuritzkes D R. HIV-1 entry inhibitors: An overview. Curr Opin HIV AIDS, 2009, 4: 82-87.
12. Qian K, Morris-Natschke S L, Lee K H. HIV entry inhibitors and their potential in HIV therapy. Med Res Rev, 2009, 29: 369-393.
13. Al-Mawsawi L Q, Al-Safi R I, Neamati N. Anti-infectives: Clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs, 2008, 13: 213-225.
14. Engelman A. Mechanistic and pharmacological analyses of HIV-1 integration. Methods, 2009, 47: 225-228.
15. Goffinet C, Allespach I, Oberbremer L, et al. Pharmacovirological impact of an integrase inhibitor on HIV-1 cDNA Species in vivo. J Virol, 2009, doi: 10. 1128/JVI. 00683-09.
16. Mehta N, Reilly M. Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population. HIV Clin Trials, 2005, 6: 5-24.
17. Sung H, Jung Y S, Kang M W, et al. High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART. AIDS Res Human Retrovir, 2007, 23: 1223-1229.
18. Wang Y M, Dyer W B, Workman C, et al. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Curr HIV Res, 2007, 5: 235-250.
19. Chew C B, Potter S J, Wang B, et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol, 2005, 33: 206-216.
20. Garcia J M, Gao A, He P L, et al. High-throughput screening using pseudotyped lentiviral particles: A strategy for the identification of HIV-1 inhibitors in a cell-based assay. Antiv Res, 2009, 81: 239-247.
21. Kempf M C, Jones J, Heil M L, et al. A high-throughput drug screening system for HIV-1 transcription inhibitors. J Biomol Screen, 2006, 11: 807-815.
22. Ferraz R M, Aris A, Martinez M A, et al. High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor. Mol Immunol, 2006, 43: 2119-2123.
23. John S, Fletcher T M, Jonsson C B. Development and application of a high-throughput screening assay for HIV-1 integrase enzyme activities. J Biomol Screen, 2005, 10: 606-614.
24. Fakes M G, Vakkalagadda B J, Qian F, et al. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Intl J Pharm, 2009, 370: 167-174.
25. Wen Z, Stern S T, Martin D E, et al. Structural characterization of anti-HIVdrug candidate PA-457 [3-O-(3′, 3′-dimethylsuccinyl)-betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma. Drug Metab Dispos, 2006, 34: 1436-1442.
26. Cao J, Isaacson J, Patick A K, et al. High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target. Antimicrob Agents Chemother, 2005, 49: 38333841.
27. van Duyne R, Easley R, Wu W, et al. Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR. Retrovirology, 2008, 5: 40.
28. Dejucq N. HIV-1 replication in CD4+ T cell lines: The effects of adaptation on co-receptor use, tropism, and accessory gene function. J Leukocyte Biol, 2000, 68: 331-337.
29. Barin F, Brunet S, Brand D, et al. Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors. J Infect Dis, 2004, 189: 322-327.
30. Pauwels R, Andries K, Desmyter J, et al. Potent and selective inhibittion of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature, 1990, 343: 470-474.
31. Wild C, Oas T, McDanal C, et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA, 1992, 89: 10537-10541.
32. Squires K E. An introduction to nucleoside and nucleotide analogues. Antivir Ther, 2001, 6(Suppl 3): 1-14.
33. Adelson M E, Pacchia A L, Kaul M, et al. Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1. Antimicrob Agents Chemoth (Bethesda), 2003, 47: 501-508.
34. Miyake H, Iizawa Y, Baba M. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests. J Clin Microbiol, 2003, 41: 2515-2521.
35. Blair W S, Isaacson J, Li X, et al. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antivir Res, 2005, 65: 107-116.